Latest News about AMGN
Recent news which mentions AMGN
Amgen's Options: A Look at What the Big Money is Thinking
December 28, 2023
Tickers
AMGN
From Benzinga
Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years
December 26, 2023
From Benzinga
Analyzing Amgen In Comparison To Competitors In Biotechnology Industry
December 25, 2023
From Benzinga
Spotlight on Amgen: Analyzing the Surge in Options Activity
December 21, 2023
Tickers
AMGN
From Benzinga
3 Biotech Stocks to Buy in the TradeSmith ‘Green Zone’
December 21, 2023
From InvestorPlace
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
December 20, 2023
From InvestorPlace
Amgen Provides Exposure To Obesity Drug At A Reasonable Price, Says Bullish Analyst
December 19, 2023
Tickers
AMGN
From Benzinga
In-Depth Examination Of 18 Analyst Recommendations For Amgen
December 19, 2023
Tickers
AMGN
From Benzinga
Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
December 19, 2023
From Benzinga
1 Biotech Stock That Could Be the Next Amgen
December 13, 2023
From Motley Fool
Better Growth Stock: Viking Therapeutics or Iovance Biotherapeutics?
December 12, 2023
From Motley Fool
PVH To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
December 12, 2023
From Benzinga
Insights Into Amgen's Performance Versus Peers In Biotechnology Sector
December 11, 2023
Tickers
AMGN
From Benzinga
1 Spectacular Dividend Stock Every Investor Should Consider
November 28, 2023
Tickers
AMGN
From Motley Fool
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
November 22, 2023
From MarketWatch
10 Health Care Stocks Whale Activity In Today's Session
November 15, 2023
From Benzinga
2 Top Biotech Stocks to Buy Right Now
November 10, 2023
From Motley Fool
Amgen's Rare Autoimmune Disease Candidate Shows Improvement In Disease Burden In Treating Sjögren's Syndrome
November 08, 2023
Tickers
AMGN
From Benzinga
The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman – and Martin Shkreli
November 06, 2023
From MarketWatch
Amgen Wins Big With FDA, Analyst Sees Soaring Potential
November 02, 2023
From Benzinga